You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, March 2017
|
| DOI | 10.1128/aac.02243-16 |
| Pubmed ID | |
| Authors |
Steven Marshall, Andrea M. Hujer, Laura J. Rojas, Krisztina M. Papp-Wallace, Romney M. Humphries, Brad Spellberg, Kristine M. Hujer, Emma K. Marshall, Susan D. Rudin, Federico Perez, Brigid M. Wilson, Ronald B. Wasserman, Linda Chikowski, David L. Paterson, Alejandro J. Vila, David van Duin, Barry N. Kreiswirth, Henry F. Chambers, Vance G. Fowler, Michael R. Jacobs, Mark E. Pulse, William J. Weiss, Robert A. Bonomo |
| Abstract |
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram negative bacteria, we tested the effectiveness of the combination of ceftazidime/avibactam (CAZ/AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). Disk-diffusion and agar based antimicrobial susceptibility testing were initially performed to determine the in vitro efficacy of a unique combination of CAZ/AVI and ATM against 21 representative Enterobacteriaceae isolates with a complex molecular background that included blaIMP, blaNDM, blaOXA-48, blaCTX-M, blaAmpC, and combinations thereof. Time-kill assays were conducted, and the in vivo efficacy of this combination was assessed in a murine neutropenic thigh infection model. By disk diffusion assay, all 21 isolates were resistant to CAZ/AVI alone, and 19/21 were resistant to ATM. The in vitro activity of CAZ/AVI in combination with ATM against diverse Enterobacteriaceae possessing MBLs was demonstrated in 17/21 isolates, where the zone of inhibition was ≥ 21 mm. All isolates demonstrated a reduction in CAZ/AVI agar dilution MICs with the addition of ATM. At 2 h, time-kill assays demonstrated a ≥ 4 log10 CFU decrease for all groups that had CAZ/AVI plus ATM (8 μg/ml) added, compared to the CAZ/AVI alone group. In the murine neutropenic thigh infection model, an almost 4 log10 reduction in CFUs was noted at 24 h for CAZ/AVI (32 mg/kg q8h) plus ATM (32 mg/kg q8h) vs. CAZ/AVI (32 mg/kg q8h) alone. The data presented herein, requires us to carefully consider this new therapeutic combination to treat infections caused by MBL-producing Enterobacteriaceae. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 15 | 48% |
| Spain | 3 | 10% |
| United Kingdom | 2 | 6% |
| Australia | 2 | 6% |
| Korea, Democratic People's Republic of | 1 | 3% |
| Malaysia | 1 | 3% |
| South Africa | 1 | 3% |
| Unknown | 6 | 19% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 48% |
| Scientists | 8 | 26% |
| Practitioners (doctors, other healthcare professionals) | 6 | 19% |
| Science communicators (journalists, bloggers, editors) | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 194 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 194 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 27 | 14% |
| Student > Bachelor | 22 | 11% |
| Other | 20 | 10% |
| Student > Master | 19 | 10% |
| Student > Ph. D. Student | 13 | 7% |
| Other | 36 | 19% |
| Unknown | 57 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 23% |
| Immunology and Microbiology | 24 | 12% |
| Biochemistry, Genetics and Molecular Biology | 14 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 6% |
| Agricultural and Biological Sciences | 8 | 4% |
| Other | 18 | 9% |
| Unknown | 73 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 103. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2023.
All research outputs
#413,243
of 25,498,750 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#107
of 15,607 outputs
Outputs of similar age
#8,659
of 323,151 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#8
of 245 outputs
Altmetric has tracked 25,498,750 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 15,607 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,151 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 245 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.